Novo Nordisk A/S: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Novo Nordisk in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Novo Nordisk's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for Novo Nordisk over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Novo Nordisk's performance against key rivals in the prescription pharmaceutical sector* Assess the impact of the delay to Amylin and Eil Lilly's Bydureon on Novo Nordisk's Victoza sales performance out to 2015

[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Novo Nordisk: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
Diabetes market overview
[Missing title]
Key antidiabetic product classes
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest comment
Q3 2010
Q2 2010 – Q1 2009
Latest prescription pharma product news
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Latest corporate news
Q3 2010
Q2 2010
Q1 2010
Q3 2009 - Q4 2009
Q2 2009
Q1 2009
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Divestments promote Rx pharma focus
Novo Nordisk and Novozymes demerger
Demerger of Zymogenetics
Acquisition of Biobrãs and Pharmaplan GmbH
Current corporate structure
Novo Nordisk business unit structure
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS AND COMPETITORS
Overview
Endocrine, metabolic & genetic disorders
NovoRapid
NovoMix
Victoza
Levemir
Actraphane
Norditropin
Hematology
NovoSeven
APPENDIX
References
Abbreviations
Exchange rates

[Inhaltsverzeichnis ausblenden]